Immune checkpoints, including PD-1/PD-L1, play an important role in immunosuppression in various malignancies. Elevated levels of soluble programmed death ligand 1 (sPD-L1) are associated with worse prognosis in multiple myeloma and diffuse large B cell lymphoma. Herein, the purpose of this study is to investigate the relationships between plasma sPD-L1 levels and clinical response in peripheral T-cell lymphoma (PTCL) patients.
| MATERIALS AND METHODS
Data from three cohorts, including 11 ALCL patients, 28 PTCL-NOS patients, and 81 matched normal control tissues, were obtained from the ONCOMINE database (https://www.oncomine.org) for PD-L1 gene expression array. The comparison dataset analysis of PD-L1 mRNA levels among diverse PTCL subtypes and matched normal control tissues was performed.
A total of 37 patients with PTCLs were enrolled in our study, and all patients were newly diagnosed, and diagnoses were further confirmed by two independent pathologists. All PTCL patients were Immunohistochemical staining of PD-L1 in FFPE tumor specimen was performed using the streptavidin-peroxidase method (SP method). Firstly, the 4 to 5-μm thickness FFPE slides were deparaffinized and rehydrated in three times of dimethylbenzene for 10 minutes each, two times of 100% ethanol for 5 minutes each, 95% alcohol for 5 minutes, and 70% alcohol for 1 minute. Antigen retrieval was carried out using EDTA buffer (pH 8.0) in 120°C for 3 minutes using microwave incubation; 0.3% hydrogen peroxide was used for blocking endogenous peroxidase activity in dark place at room temperature for 10 minutes. Then, they were incubated with anti-PD-L1 primary antibody (1:200, clone: E1L3N, Cell Signaling Technology, MA, USA) at 4°C overnight and were then incubated with secondary antibody rabbit IgG/HRP for 30 minutes at 37°C. The slides were counterstained with hematoxylin and covered under coverslips.
If ≥5% of the total tissue cells showed membrane staining, it was defined as high PD-L1 expression.
The status of Epstein-Barr virus (EBV)-encoded RNA (EBER) was evaluated to detect the EBV infection by in situ hybridization using a Novocastra ISH Kit (Novocastra Laboratories, Newcastle upon Tyne, UK) on 4 to 5-μm thickness slides according to the manufacturer instructions.
Statistical analyses SPSS 19 .0 statistical software and Graphpad Prism v8.0 were utilized for statistical analyses. The correlations between sPD-L1 and IFN-γ levels were analyzed using Pearson's chi-squared test. And the relationships between sPD-L1 levels and clinicopathologic parameters were assessed using Fisher's exact test. Multivariate analyses for clinical response were performed using the binary logistic regression (LR) model. The cut-off values for sPD-L1 levels were initially set as the median level and were also optimized using the receiver operating characteristic (ROC) curve analyses. Overall response rate (ORR) was defined as the proportion of patients with confirmed complete response or partial response. Progression-free survival (PFS) was defined as the time from diagnosis to disease progression or death without evidence of progression. Overall survival (OS) was defined as the time from diagnosis to death or date of last follow-up. A logrank test was used for comparison, and P < .05 was considered statistically significant.
| RESULTS

| Transcription levels of PD-L1 in PTCL patients
We compared the transcriptional levels of PD-L1 from three PTCLs cohorts with those in matched normal control tissue by using the ONCOMINE database ( Figure 1 ). We found that the PD-L1 mRNA expression was upregulated in PTCLs, which were significantly higher in PTCLs compared with matched normal control tissues (one cohort, 0.029; two cohorts, 0.020; and three cohorts, 0.021).
| Patient characteristics
The baseline characteristics of 37 PTCL patients were summarized in 
| Plasma sPD-L1 and IFN-γ levels
As shown in Figure 2 , the median level of sPD-L1 of PTCL patients was 1.696 ng/mL, which was much higher than that of healthy volunteers (0.729 ng/mL, 0.000). The median level of IFN-γ of PTCL patients was 4.555 pg/mL. Further analysis showed that the levels of sPD-L1 were positively correlated with the level of IFN-γ (0.000, r = 0.849).
The cut-off value of sPD-L1 was initially set as the median level ( 
| Correlation between sPD-L1 level and clinical response
After receiving at least four cycles treatment, five of all patients lost the clinical information, 11 patients showed a complete response (CR), 12 patients showed a partial response (PR), three patients showed a stable disease (SD), and six patients showed a progressive disease (PD). According to the cut-off value of sPD-L1 levels (median level, 1.696 ng/mL), as shown in Figure 3A , the ORR was 88.9% in low sPD-L1 level group, which was significantly higher than that of high sPD-L1 level group (50.0%, 0.022). Based on the ROC curve analyses, the optimal cut-off value of sPD-L1 levels for clinical response was 1.575 ng/mL, the area under the ROC curve was 0.773, and the sensitivity was 88.9% and specificity was 70.9%. According to the optimal cut-off value of sPD-L1 levels, the ORR was 93.3% in low sPD-L1 level group, which was also significantly higher than that of high sPD-L1 level group (52.9%, 0.018, Figure 3B ). We further divided these patients into three cohorts according to sPD-L1 level, including low, median, and high. We found that when the cut-off values of sPD- Table 2 ). These results displayed that high sPD-L1 levels were correlated with worse clinical response, suggesting that sPD-L1 levels were an underlying plasma biomarker to predict the clinical response in PTCL patients.
| Correlation between sPD-L1 level and survival
The survival analysis revealed that the median PFS for high and low sPD-L1 level groups was 42.7 months (95% CI, 27.9-57.6) and 53 months (95% CI, 33.7-72.3), respectively. As well, the median OS for high and low sPD-L1 level groups was 48.3 months (95% CI, 35.2-61.2) and 71 months (95% CI, 51.0-90.9), respectively. However, there were too few patients for a statistical significance for PFS (log-
FIGURE 2 Level of plasma sPD-L1 in PTCL patients and healthy volunteers
FIGURE 3
The overall response rate between high and low sPD-L1 level groups according to the cut-off value of median sPD-L1 levels (A) and the optimal cut-off value of sPD-L1 levels (B) rank test, 0.904) and OS (log-rank test, 0.896). But these results suggested at least that patients with high sPD-L1 levels tended to have shorter PFS and OS than those with low sPD-L1 levels.
| Association between sPD-L1 and tissue PD-L1 expression
Eleven matched FFPE specimen from patient tumor biopsies, including three NKTCL, one ALCL, three AITL, three PTCL-NOS, and one unknown PTCL subtype, were available. IHC staining results displayed that five patients had low tissue PD-L1 expression, which matched with the patients with low sPD-L1 level ( Figure 5A ). These patients Previous report showed that the sPD-L1 was produced by matrix metalloproteinases from immune and tumor cells. 24 However, the accurate sources of sPD-L1 remain unclear. Generally, soluble forms of receptors or ligands are usually produced through proteolytic cleavage of membrane-bound proteins, such as sTNF and sB7-H3, 24, 25 or by translation of alternative spliced mRNA, such as sCD86. 26 Report has suggested that IFN-γ can induce upregulation of PD-L1 expression. 7, 27 In this study, we indeed found that the levels of sPD-L1 were positively correlated with IFN-γ level in PTCL patients. It further suggested that IFN-γ could upregulate the sPD-L1 level in PTCLs. Studies have reported that elevated sPD-L1 level is associated with poor prognosis in renal cell carcinoma and DLBCL. 19 Among the patients with renal cell carcinoma, higher sPD-L1 levels are associated with larger tumors, tumors with necrosis, and advanced stage and high grade.
High sPD-L1 levels are also reported to be an independent prognostic factor for poorer PFS in multiple myeloma. 28 These results suggest that sPD-L1 levels have a potentiality instead of tissue PD-L1 level to predict the anti-immune response for some subtypes of tumors.
In our study, we found that sPD-L1 levels in PTCL patients were much higher than that in healthy volunteers. We also found that patients with lower sPD-L1 level always had good clinical response (high ORR) and tended to have an excellent survival. However, a statistical significance was not found for OS and PFS analysis. The reason may be that the sample size is too small. A study of enlarged sample size needs to be developed to further verify our findings. In addition, our study revealed that patients with elevated LDH level, advanced stage, and elevated β2-MG level had higher sPD-L1 levels, which also FIGURE 4 Three cohorts of PTCL patients with low (green), median (blue), and high (red) sPD-L1 level. The threshold of cut-off values between low and median cohorts was 1.2, and the threshold of cut-off values between median and high cohorts was 2.6. The optimal cut-off value was 1.575 suggested that sPD-L1 levels had a potential effect to predict PTCL progression. Studies have also confirmed that PD-L1 expression in tumor tissue could affect the patient prognosis by tumor-intrinsic signaling and adaptive immunosuppression. [29] [30] [31] In order to reveal the association between sPD-L1 level and tissue PD-L1 expression in PTCLs, we detected the expression of tissue PD-L1 in some matched patients by IHC. Our results showed that it exhibited a high matched rate between sPD-L1 level and tissue PD-L1 expression for these patients. However, because of the heterogeneity among tumors, the matched rate between sPD-L1 level and tissue PD-L1 expression can be different in diverse malignancies. Previous study has reported that no association is found between sPD-L1 level and tissue PD-L1 expression in DLBCL. 19 But another study reported that sPD-L1 level positively corrected with tissue PD-L1 expression, suggesting a high matched rate, in NKTCL, 32 which is similar to our results in PTCLs.
Except for the heterogeneity among tumors, another reason for these different results may also be due to different sources of PD-L1 antibodies. Another important study has identified that different sources of PD-L1 antibodies will raise some questions about their similarity and the potential interchangeability of the tests, and they found that three of four PD-L1 antibodies, including 22c3, 28-8, and E1L3N, were concordant and reproducible as read by pathologists; however, SP142 was an outlier. 33 The same sourced PD-L1 antibody (E1L3N)
is used in PTCLs in our study and in NKTCL, 32 which may be a potential reason for the concordant results in the two studies. However, another sourced PD-L1 antibody (ab58810) is selected in DLBCL. 19 In conclusion, high sPD-L1 level was associated with poor clinical response and tended to have shorter PFS and OS for PTCL patients. 
